GPCR实时信号 | 通过Getagraph.com最大化利润

购买 107629 min ago

@ $46.21

发出时间: 15 Feb 2024 @ 01:06

回报率: -15.72%

上一信号: Feb 14 - 22:30

上一信号: 出售

回报率: -4.71 %

Live Chart Being Loaded With Signals

Commentary (27 Apr 2024 @ 04:00):

Structure Therapeutics Inc., a clinical stage global biopharmaceutical company, develops and delivers novel oral therapeutics to treat a range of chronic diseases with unmet medical needs...

Stats
今日成交量	972 594
平均成交量	576 859
市值	1.81B
EPS	$-0.620 ( 2023-11-14 )
下一个收益日期	( $-0.210 ) 2024-05-09
Last Dividend	$0 ( N/A )
Next Dividend	$0 ( N/A )
P/E	-16.02
ATR14	$0.114 (0.29%)

Insider Trading

Date	Person	Action	Amount	type
2024-04-17	Fmr Llc	Buy	0
2024-03-15	Lin Xichen	Buy	213 486	Stock Option (right to buy)
2024-03-15	Bach Mark Allen	Buy	65 352	Stock Option (right to buy)
2024-03-15	Ma Yingli	Buy	91 494	Stock Option (right to buy)
2024-03-15	Yoon Jun	Buy	148 134	Stock Option (right to buy)

INSIDER POWER
30.31
Last 43 transactions
Buy: 9 065 015 \| Sell: 6 065 489

音量相关性

長: -0.07 (neutral)

短: -0.73 (moderate negative)

Signal:(43.039) Neutral

Structure Therapeutics 相关性

10 最正相关

10 最负相关

你知道吗？

相关性是描述两个变量之间关系的统计指标。它的取值范围为-1到1，其中-1表示完全负相关（一个变量增加，另一个变量减少），1表示完全正相关（一个变量增加，另一个变量也增加），0表示没有相关性（变量之间没有关系）。

相关性可用于分析任何两个变量之间的关系，而不仅仅是股票。它通常用于金融、经济学、心理学等领域。

Structure Therapeutics 相关性 - 货币/商品

0.77
( moderate )

0.84
( strong )

0.00
( neutral )

0.81
( strong )

-0.71
( moderate negative )

-0.80
( moderate negative )

Structure Therapeutics 财务报表

Annual	2023
营收:	$0
毛利润:	$-949 174 (0.00 %)
EPS:	$-2.44

FY	2023
营收:	$0
毛利润:	$-949 174 (0.00 %)
EPS:	$-2.44

FY	2022
营收:	$0
毛利润:	$-623 258 (0.00 %)
EPS:	$-1.400

Financial Reports:

No articles found.

Structure Therapeutics

Structure Therapeutics Inc., a clinical stage global biopharmaceutical company, develops and delivers novel oral therapeutics to treat a range of chronic diseases with unmet medical needs. Its lead product candidate is GSBR-1290, an oral and biased small molecule agonist of glucagon-like-peptide-1 receptor, a validated G-protein-coupled receptors (GPCRs) drug target for type-2 diabetes mellitus and obesity. The company is also developing oral small molecule therapeutics targeting other GPCRs for the treatment of pulmonary and cardiovascular diseases, including ANPA-0073, a biased agonist, targeting apelin receptor, a GPCR that has been implicated in idiopathic pulmonary fibrosis (IPF) and pulmonary arterial hypertension; and LTSE-2578, an investigational oral small molecule lysophosphatidic acid 1 receptor antagonist for the treatment of IPF. The company was formerly known as ShouTi Inc. Structure Therapeutics Inc. was founded in 2016 and is headquartered in South San Francisco, California.